Overview

Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether Chinese medicinal herbs are effective and safe for treating novel influenza A (H1N1) infection.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Capital Medical University
Treatments:
Antiviral Agents
Oseltamivir
Criteria
Inclusion Criteria:

- Confirmed novel influenza A(H1N1) case with laboratory evidence

- 70 years ≥ age ≥ 14years

- Within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one
respiratory symptom (cough, sore throat, or nasal symptom)

Exclusion Criteria:

- Age < 14 years or > 70 years

- Bronchitis, pneumonia, pleural fluid and interstitial infiltration showed by Chest
radiology(x-ray or CT)

- Severe chronic underlying diseases: severe COPD(FEV1/EVC <70% and FEV1 <30% predicted
or respiratory failure or congestive heart failure), severe hepatic disfunction(ALT or
AST ≥3 times normal elevation), renal disfunction(Cr>2mg/dL), chronic heart
failure(NYHA Ⅲ-Ⅳ grade)

- Immunocompromised patients(cancer, organ transplant, AIDS and a history of treatment
with immunosuppressive drug and glucocorticoids in the past 3 months)

- Taken Chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks

- Inoculation influenza vaccination

- One of the following items appeared at the enrollment

- respiratory failure:PaO2<60mmHg and/or PCO2>50mmHg or PaO2/FiO2≤300

- circulation failure: despite adequate fluid resuscitation and cardiac output,
systolic <90mmHg or requirement inotropic support

- renal function failure: despite adequate fluid resuscitation and cardiac output,
urine ≤ 0.5ml/kg.h, Cr or BUN≥1 time normal elevation

- hepatic function failure: total bilirubin>34μmol/L or ALT/AST ≥3 times normal -
Other unappropriated enrollment situations considered by investigator